Promis Neurosciences (NASDAQ:PMN) Raised to Hold at Zacks Research

Promis Neurosciences (NASDAQ:PMN) was upgraded by Zacks Research to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Several other research analysts have also recently issued reports on PMN. Brookline Capital Markets upgraded Promis Neurosciences to a “strong-buy” rating in a research note on Wednesday, May 20th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Promis Neurosciences in a research note on Monday. Finally, Wall Street Zen upgraded Promis Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $26.50.

Promis Neurosciences Stock Performance

Promis Neurosciences stock opened at $10.20 on Tuesday. The stock has a 50-day moving average of $10.97 and a two-hundred day moving average of $12.04. Promis Neurosciences has a one year low of $6.27 and a one year high of $39.75. The stock has a market cap of $91.49 million, a PE ratio of -0.70 and a beta of -0.19.

Promis Neurosciences (NASDAQ:PMN) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.20). As a group, sell-side analysts predict that Promis Neurosciences will post -4.57 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Patrick D. Kirwin purchased 4,000 shares of Promis Neurosciences stock in a transaction that occurred on Wednesday, April 22nd. The stock was bought at an average cost of $11.33 per share, for a total transaction of $45,320.00. Following the completion of the transaction, the director owned 4,653 shares in the company, valued at $52,718.49. The trade was a 612.56% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PMN. Ally Bridge Group NY LLC raised its position in Promis Neurosciences by 367.1% during the third quarter. Ally Bridge Group NY LLC now owns 6,233,497 shares of the company’s stock valued at $2,649,000 after acquiring an additional 4,899,069 shares in the last quarter. Janus Henderson Group PLC purchased a new position in Promis Neurosciences during the first quarter valued at approximately $16,418,000. Armistice Capital LLC raised its position in Promis Neurosciences by 39.1% during the third quarter. Armistice Capital LLC now owns 2,974,518 shares of the company’s stock valued at $1,264,000 after acquiring an additional 836,622 shares in the last quarter. Yu Fan purchased a new position in Promis Neurosciences during the first quarter valued at approximately $4,188,000. Finally, Citadel Advisors LLC raised its position in Promis Neurosciences by 168.1% during the third quarter. Citadel Advisors LLC now owns 170,079 shares of the company’s stock valued at $72,000 after acquiring an additional 106,650 shares in the last quarter. 50.13% of the stock is currently owned by hedge funds and other institutional investors.

More Promis Neurosciences News

Here are the key news stories impacting Promis Neurosciences this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Promis Neurosciences and maintained an $18.00 price target, signaling meaningful upside versus the current trading level. Source: MarketBeat PMN analyst updates
• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate for PMN, which can be viewed as a modest improvement in the medium-term earnings outlook. Source: MarketBeat PMN analyst updates
• Neutral Sentiment: Zacks Research upgraded Promis Neurosciences to Hold, which is better than a downgrade but does not point to strong near-term upside. Source: Zacks.com
• Negative Sentiment: Several HC Wainwright quarterly EPS estimates for 2026 and 2027 are still deeply negative, and the firm lowered its Q4 2026 estimate, which may weigh on sentiment. Source: MarketBeat PMN analyst updates
• Negative Sentiment: The stock was also highlighted in an article noting it was down sharply, suggesting investors are reacting to the weak earnings profile and ongoing volatility. Source: AAII article

Promis Neurosciences Company Profile

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.